Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin Article

Full Text via DOI: 10.1111/dom.13199 PMID: 29272064 Web of Science: 000430070000023
Industry Collaboration International Collaboration

Cited authors

  • Zhou, Fang Liz; Ye, Fen; Berhanu, Paulos; Gupta, Vineet E.; Gupta, Rishab A.; Sung, Jennifer; Westerbacka, Jukka; Bailey, Timothy S.; Blonde, Lawrence

Abstract

  • This retrospective cohort study compared real-world clinical and healthcare-resource utilization (HCRU) data in patients with type 2 diabetes using basal insulin (BI) who switched to insulin glargine 300 units/mL (Gla-300) or another BI. Data from the Predictive Health Intelligence Environment database 12 months before (baseline) and 6 months after (follow-up) the switch date (index date, March 1, 2015 to May 31, 2016) included glycated haemoglobin A1c (HbA1c), hypoglycaemia, HCRU and associated costs. Baseline characteristics were balanced using propensity score matching. Change in HbA1c from baseline was similar in both matched cohorts (n = 1819 in each). Hypoglycaemia incidence and adjusted event rate were significantly lower with Gla-300. Patients switching to Gla-300 had a significantly lower incidence of HCRU related to hypoglycaemia. All-cause and diabetes-related hospitalization and emergencydepartment HCRU were also favourable for Gla-300. Lower HCRU translated to lower costs in patients using Gla-300. In this real-world study, switching to Gla-300 reduced the risk of hypoglycaemia in patients with type 2 diabetes when compared with those switching to another BI, resulting in less HCRU and potential savings of associated costs.

Publication date

  • 2018

Published in

International Standard Serial Number (ISSN)

  • 1462-8902

Start page

  • 1293

End page

  • 1297

Volume

  • 20

Issue

  • 5